Plain-English translation of NCT07668557 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing ICG415, a new type of therapy that uses your own immune cells to fight acute myeloid leukemia (AML)—a serious blood cancer that has stopped responding to standard chemotherapy. The treatment involves collecting your immune cells, training them in a laboratory to recognize and attack leukemia cells, and then giving them back to you as an infusion. Researchers want to learn whether this medication is safe and whether it can help patients whose cancer has come back or resisted other treatments.
Standard chemotherapy doesn't work well for people whose AML has relapsed or become resistant to treatment, and these patients have very few other options. This new treatment targets two specific markers on leukemia cells while sparing healthy blood-forming cells, which may make it safer and more effective than current approaches.
You likely qualify if…
You likely don't qualify if…
First, you will undergo blood work and tests to confirm you qualify for the study. If you do, doctors will collect some of your immune cells through a procedure called leukapheresis. These cells are then sent to a lab where they are modified to recognize your leukemia. While waiting, you will receive chemotherapy to prepare your body. Once the modified cells are ready, you will receive them back as an infusion. After that, you will be monitored closely with regular blood tests, imaging, and clinical visits for up to 2 years to watch for side effects and signs that the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China